- Home
- NCZ vs NERV Comparison
NCZ vs NERV Comparison
Compare NCZ & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | NERV |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 231.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NCZ | NERV |
|---|---|---|
| Price | $14.80 | $3.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 39.7K | ★ 120.7K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.95 | $1.93 |
| 52 Week High | $16.17 | $12.46 |
Technical Indicators
Market Signals| Indicator | NCZ | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 31.76 | 35.75 |
| Support Level | $14.78 | N/A |
| Resistance Level | $14.86 | $4.73 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 12.15 | 12.62 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of current income, current gains and long-term capital appreciation. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.